Boston Scientific will distribute Veniti’s Vici venous stent under a limited global distribution agreement. The terms of the agreement and specific regions and countries involved have not been disclosed.
Launched in 2014, the Vici venous stent has gained wide market acceptance for the unique balance of end-to-end strength, flexibility and lumen quality for addressing the challenging requirements of venous disorders. It is available in a conventional delivery system, as well as the novel Vici Verto venous stent system, providing more control in the landing of stents in areas of critical blood flow.
“The Vici venous stent is widely recognised as state-of-the-art technology for venous stents and physicians routinely praise the product for its performance qualities. We are extremely pleased to be partnering with a global industry leader like Boston Scientific to advance the Vici venous stent in the marketplace,” said Jeff Elkins, president and CEO of Veniti. “Boston Scientific’s market leadership and reach will provide more physicians treating patients suffering from venous outflow obstruction around the world greater access to leading-edge technology.”
Venous obstructive disease affects more than 1.1 million people in the USA and Western Europe annually. Deep venous thrombosis is one of the most common and serious conditions associated with chronic venous disease and the financial impact is well established. Physicians treat the obstructive component of chronic venous disease through minimally-invasive endovascular stenting procedures. Veniti is currently conducting the VIRTUS trial to evaluate the safety and efficacy of the Vici venous stent for the treatment of chronic iliofemoral venous outflow obstruction under a US Food and Drug Administration Investigational Device Exemption.
